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Parkinson's disease (PD) is one of the most common neurodegenerative disorders of the elderly population. Few
therapeutic options are available for patients with PD requiring palliative care. Treatment of the early stages of PD is
entirely different from later stages. During the later stages, the palliative care model is introduced to provide the
patient with comfort and support. Early palliative care in PD requires minimization of dyskinesias and decreasing
occurrence of motor and non-motor off times in an effort to maximize independent motor function. In the later
stages, the focus of treatment shifts to treating the predominant non-motor symptoms and having a more
supportive and palliative nature. The purpose of this review is to provide a summary of the palliative care
management issues and palliative care management options of end-stage PD patients.
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Parkinson's disease (PD) is one of the most common
neurodegenerative disorders of the elderly population
with an average age of onset of 60 years of age [1]. PD
affects 17.4 per 100,000 of individuals between the ages
of 50-59 and 93.1 people per 100,000 of individuals be-
tween the ages of 70-79 [2,3]. The average patient lives
15 years from the time of diagnosis until death [4]. PD is
currently assessed as more of a systemic brain disease
with many different dysfunctional or dying neuronal cell
systems thus affecting different transmittor substances
and not only a loss of specific dopaminergic neurons in
the substantia nigra. As PD progresses, there is a also
presence of Lewy bodies within the cytoplasm of the
affected dopaminergic neurons and a hierarchical spread
of these within the brain from the medulla oblongata
through the substantia nigra to the cortex. The PD
course could be described as passing through a trajec-
tory of phases starting with a “honey-moon” phase with
an almost complete symptom relief due to pharmaco-
logical treatment, followed by a motor complication
phase, neuropsychiatric phase, and ending up in the* Correspondence: ahmad.delbari@ki.se
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distribution, and reproduction in any mediumpalliative phase. However, this is only a way to describe
the inevitable progression of the disease as many symp-
toms may occur during all stages of the disorder. Unfor-
tunately, few therapeutic options are available for PD
patients who have progressed to more advanced disease
[5]. There are several therapeutic options for advanced
PD patients including intraduodenal levodopa infusion,
apomorphine infusion and deep brain stimulation. They
have different profiles and are addressing different PD
phenotypes. However, end-stage PD patients, especially
if they are cognitively impaired as they often are, exclude
them from these therapies. Medical interventions are
largely ineffective in preventing the inevitable progres-
sion of PD since there is always also a possibility of an
intercurrent illness. Additionally, there is a high prob-
ability of PD patients to become disabled and dependent
[6]. PD patients who do not respond to standard treat-
ments require multidisciplinary care that include ele-
ments of traditional medicine and holistic care. In this
multidisciplinary care model, treatment of common
non-motor symptoms like pain and depression are com-
plemented with holistic therapies including psycho-
logical, social and spiritual problems that might arise [7].
According to the World Health Organization (2005)
palliative care is to provide comfort and support for
people who are facing life-threatening illnesses in order
to improve the quality of their lives as well as those oftral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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ness, assessing, and treating the pain as well as other
physical, psychological and spiritual problems that might
cause suffering.
In order to maximize the quality of life for these
patients, the palliative care must include a team of med-
ical providers, nurses, as well as additional caregivers
[9]. Such an approach serves to provide traditional med-
ical therapies, emotional and spiritual support while pre-
serving patient autonomy and dignity as they manage
their disease. Treatment of the early stages of PD is en-
tirely different from later stages. Early treatment is
geared towards prevention, symptom relief enhancement
of survival, and prevention of motor symptoms. During
the later stages, the palliative care model is introduced
to provide the patient with comfort and support. In the
later stages, however, the focus of treatment shifts to
treating non-motor symptoms and having a more sup-
portive and palliative nature. That is why, as the patient
approaches the end-stage of the illness, the main goal of
both the patient and the physician becomes manage-
ment of motor and non-motor impediments according
to the principles of palliative care. It is important to take
into account that symptom control care includes the
preserving of autonomy as well as stress relief. A holistic
approach must be applied from the moment of diagnosis
until the end of a patient’s life and should not only be
reserved for the stage of bereavement.
The purpose of this review is to provide a short sum-
mary of some of the palliative care issues of end-stage
PD from a clinical and pragmatic point of view and
discusses how patients can be treated through the appli-
cation of common principles of palliative care manage-
ment. References for this review were recognized
through search in PubMed for potentially relevant arti-
cles with the search terms of “Parkinson’s disease”, “pal-
liative care”, and “advanced Parkinson’s disease. The
review is focusing on the medical management of motor
and non-motor manifestations and concentrates on end-
stage PD patients.
Pharmacologic issues at end-stage Parkinson's disease
As PD progresses there are fewer dopaminergic neurons
in the substantia nigra as well as a progressively lower
capacity to store exogenous levodopa and convert it to
dopamine for storage and release in the remaining neu-
rons. Additionally, as the dose requirements of levodopa
increase, the patient's functioning is inhibited before his
next dose of medication [10]. This usually takes place 2–4
hours after a levodopa dose and may appear as sensory
(pain, paraesthesiae), psychiatric (paranoia, anxiety, hallu-
cinations, depression) or autonomic (sweating, belching,
constipation, tachycardia, or breathlessness) symptom, or
progression of motor symptoms or dystonia [11]. This iscalled “end of dose wearing off”. Wearing off has not been
fully explored, but may be connected to pharmacokinetic
changes, and shortening of striatal levodopa half-life
resulting from progressive degeneration of nigrostriatal
dopaminergic terminals [12]. To treat motor symptoms it
is necessary to deliver medication effectively. Patients with
advanced PD often notice that protein-rich meals will di-
minish the effectiveness of levodopa doses [13]. This can
be alleviated by reducing protein intake during daytime
and limiting protein intake at night to 40 grams [9]. There
are some strategies to Improve absorption of Levodopa in-
clude: advise patients to take levodopa before meals, on an
empty stomach [14], advise patients to avoid protein-rich
meals and bulk-forming foods [15], advise patients against
lying down, and encourage them to move around, after
ingesting a dose [16], and advise patients to mix levodopa,
crushed into a powder, into sparkling liquid [17].
As the disease progresses, current levodopa doses give
hyperkinesia due to the narrowing of the therapeutic
window. In addition, patients on polypharmacy regimens
are often on other anti PD drugs that commonly elicit
side effects like hallucinations and/or dyskinesia. This
implies that the patient often must have monotherapy
with levodopa as this drug is least prone to have side
effects and that the doses must be lower and carefully
monitored.
Motor complications
Motor complications in PD consists of motor fluctua-
tions and dyskinesia most probably as a result of the
pharmacological treatment. These can be either exces-
sive hypokinesia (e.g. freezing, rigidity, increasing off
times, dysphagia, dysarthria, and respiratory comprom-
ise) or excessive hyperkinesia (e.g. choreiform and dys-
tonic dyskinesia). Motor complications decrease the
patient's quality of life in many ways as they affect emo-
tional health, decrease mobility, decrease independence
for activities of daily living, and cause social stigma [18].
Maintenance of independent motor function is the pri-
mary goal of treatment of early and later stages of PD.
Such a strategy allows the patient to remain independ-
ently mobile for as long as is possible, and greatly
improves quality of life. The focus of treating these
motor complications in end-stage PD needs to make the
patient as independent as possible for as long as possible
by increasing the time with no dyskinesias and decreas-
ing occurrence of motor and non-motor off times.
Hypokinesia/akinesia
Among individuals with PD, gait disorders are one of
the most common factors that affect independence and
quality of life [19]. Debilitating hypokinesia as a type of
motor fluctuation is one of the most common signs
of end-stage PD. In these individuals, episodes of
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events are typically associated with either a failure to re-
spond or the “off” phase of dopaminergic treatment [9].
Frequent dosing of short-acting levodopa/carbidopa
every 3–4 hours coupled with the catechol-o-methyl
transferase (COMT) inhibitors, are currently the best
therapy to minimize episodes of hypokinesia. This regi-
men causes the least variation of levodopa in blood
levels, with less off-time, more on-time, and better
quality of life. The COMT-inhibitor tolcapone has both
central and peripheral effects on the dopaminergic me-
tabolism in contrast to the COMT-inhibitor entacapone,
which only acts peripherally. Tolcapone is particularly
indicated in advanced patients where the otherwise most
commonly used entacapone is no longer effective [20].
Dopamine agonists are another therapeutic option al-
though they carry the risk of worsened cognition at the
end of life [21]. Additionally, longer-acting sustained-re-
lease carbidopa/levodopa regimens can be used during
sleeping hours if awakenings are accompanied by immo-
bility [22].
Dyskinesia
Among the major complications of managing PD is the
presence of dyskinesia. Dyskinesias consist of abnormal
movements (e.g. movement of the head, neck and limbs)
that are both debilitating, physically tiring, and embar-
rassing. Several reports show that the rate of this prob-
lem vary greatly, ranging from 19 to 80% in PD patients
[23]. Dyskinesias in end-stage PD are more frequent [24]
and are likely to be a consequence of long-term levo-
dopa therapy [25]. A recent study showed that PD
patients treated with levodopa for 4–6 years have a 40%
likelihood of experiencing dyskinesia [26]. Painful and
debilitating dyskinesia are less common today than 10
years ago due to more cautious, careful and individua-
lized anti-PD therapy. Lower doses of levodopa, earlier
introduction of other anti-PD agents have contributed to
this, However, once dyskinesias occur, lowering of dopa-
minergic therapy, adding inhibitors of MAO-B or
COMT as well as adding amantadine could have some
effect. However, dyskinesias don't seem to be a major
problem when the patients get demented.
Dystonia
Dystonia as a neurological movement disorder occurs in
untreated PD patients.
The treatment of dystonia varies based upon clinical
presentation. Early morning dystonia, a symptom of over-
night wearing off, may respond to nocturnal long-acting
dopaminergic agents. In contrast, peak-dose dystonia, that
occurs during the day, may respond to reduced dose of
dopaminergic medications, given more frequently in smal-
ler doses [9]. EMG guided injections of botulinum toxinscan be used to treat focal dystonia of a single muscle [27].
Anticholinergics, baclofen and benzodiazepines are regu-
larly used with caution due to possible cognitive side
effects in the end-stage PD patient [9]. The use of botu-
linum toxin (BT) is increasing in PD patients when treat-
ing dystonia, spasms, urinary bladder dysfunction and
drooling. Targeted injections of BT, often guided by EMG,
can be tried in these conditions. BT only starts having an
effect after three to four days. This effect will gradually in-
crease till about three weeks after treatment. There is no
permanent effect and the treatment needs to be repeated
after 3-4 months.
Freezing
PD patients can experience freezing of mobility through
any movement, but it is most prominent and difficult
when this freezing involves gait. Freezing is especially
frequent when initiating gait (start hesitation) and when
passing through tight spaces such as doorways [28].
Freezing can be the result of either too much or too lit-
tle dopaminergic effect. “Off freezing” may react to
changes in the aforementioned medications, while “on
freezing” is often associated with end- stage disease and
is typically difficult to handle [28]. Non-pharmacological
treatments and tricks can be used in freezing conditions
– auditory cueing by counting figures loudly or clapping
hands can be tried as well as visual cues like drawing
lines on the floor, using a cane or the light of a laser
pointer. These procedures might eliminate or diminish
freezing episodes However, these techniques may be asso-
ciated with an increased risk of falling, which PD patients
already are at risk at, and fall prevention is essential to
avoid serious fractures or injuries to the head [9].
Palliative care management of non-motor complications
Patients with PD can develop non-motor manifestations,
categorized into autonomic dysfunction, cognitive im-
pairment, neuropsychiatric disorders, and sleep distur-
bances. At the end-stage of PD, non-motor symptoms
become more common and can become the most prom-
inent medical problem, leading to increasing decline in
quality of life both for patient as well as increasing care-
giver burden [29]. Non-motor symptoms occur in up to
50% of PD patients especially in association with the
medication “off” state and may become worse by anti-
PD medications [30]. Almost one third of patients
reports their non-motor symptoms to be at least as de-
bilitating as their motor symptoms [30].
All patients with motor fluctuations face at least one
non-motor problem during the off phase [30]. In end-
stage of PD, dementia, psychosis, and falls become more
complex to manage than the motor complications; as a
result, managing non-motor aspects is important to in-
crease quality of life and decrease the burden of illness
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non-motor symptom screening questionnaire (the
“NMSQuest”), found noticeably high scores among PD
patients for impaired taste/smell, impaired swallowing,
weight loss, constipation, urinary urgency, forgetfulness,
dribbling, sadness, hallucinations, anxiety, sexual dys-
function, falling, reduced concentration, daytime sleepi-
ness, vivid dreams, and sweating [32].
Psychiatric complications
Psychosis
In most cases, psychosis develops late in PD, often due
to underlying dementia and as a result of anti PD medi-
cation use. Around 40% of PD patients develop demen-
tia in the late stages of the disease, and in these,
psychosis is common. Patients suffering from PD de-
mentia and psychosis are more likely to be placed in a
nursing home and are also at an increased mortality risk
[33]. Intercurrent medical conditions like constipation,
dehydration, electrolyte abnormalities, pneumonia or
urinary tract infection, may be hidden causes to psych-
osis and should be investigated and treated appropriately
before starting antipsychotic treatment. Psychosis usually
develops late in PD, often due to underlying dementia
and as a result of anti-PD medication. However, it can
occur throughout the whole trajectory of the disease.
The first step for psychosis treatment is to discontinue
or decrease likely offending agents in the hierarchic
order of anticholinergics, MAO-B inhibitors (MAO-BI,
amantadine, dopamine agonists, and eventually levodopa
[34]. However, there is then a risk of the patient having
more motor problems. The physician should resort to
atypical antipsychotics as the only remedy in the event
psychosis persists despite best efforts to eliminate or de-
crease anti-PD drugs as being important contributors.
The atypical antipsychotics, clozapine and quetiapine are
possibly the most effective treatments, while olanzapine
probably does not improve psychosis [35]. Risperidone is
not a true atypical antipsychotic and has been found to
exacerbate PD motor symptoms [36]. In general, all
these drugs should be prescribed in low doses with slow
upwards titration in order not to cause side effects.
Moreover, acetylcholinesterase inhibitors (AChEI) may
have a beneficial effect on mild and moderate psychosis.
Depression
Depression and anxiety occur in up to 40% of all PD
patients, possibly higher among end-stage patients with
increasing motor complications [37]. Anxiety as well as
depression also tend to be more frequent during off-
periods and often getting better when the dopaminergic
treatment is optimized thus having less pronounced and
less frequent off-periods. They can both be present
throughout the disorder. Depression in the PDpopulation has the most severe negative impact on
reported quality of life [38]. In late stage PD, it is essen-
tial to closely evaluate patients, with the assistance of
family and other caregivers, to identify depression. Be-
sides from non-pharmacological treatment, antidepres-
sants are widely used especially the serotonin reuptake
inhibitors (SSRIs) [39]. Other drugs are less advisable be-
cause they carry more risk of cognitive side effects, and
this is especially true for tricyclic antidepressants. Anx-
iety is closely related to depression and it is found that
66% of PD patients with motor fluctuations experience
anxiety, often associated with irritability.
Cognitive complications
Cognitive impairment is found to occur in up to 80% of
patients after 8 years of disease duration [40]. There are
many steps when treating dementia, the first step being
discontinuing unnecessary psychotropic medications, in-
cluding amantadine, anticholinergics, sedatives, MAO-BI,
and tricyclic antidepressants. The anti-dementia drugs
used in Alzheimer's disease (AD) can also be used in PD
dementia (PDD) despite there are only sparse documenta-
tion of the effect in PDD. However, it is reasonable to
believe, and clinical experience speaks for it, that all
AChE-Is – donepezil, rivastigmine and galantamine –
show similar effects in PDD as in AD [29]. In line with
AD treatment, memantine can also be used either as
monotherapy or in combination with AChE-I in order to
have additive or synergistic effect. Randomized controlled
trials showed that the AChEIs donepezil and rivastigmine
moderately improved cognition in PD. After 24 weeks of
follow-up, some cognitive and behavioral functional
improvements were observed in patients who suffered
from mild to moderate PD treated with rivastigmine,
which now is approved for PD dementia treatment [41].
Sleep disturbance
Sleep disturbances affect up to 60% of PD patients [42].
Sleep disorders can result from motor-related aspects as
well as from non-motor-related aspects and medications.
Anticholinergic medications, MAO-BI, and dopamin-
ergic drugs can worsen the condition and must be con-
sidered to be decreased or stopped. Low-dose nightly
clonazepam or melatonin might be useful. Nocturnal
dystonia and cramping may cause sleep fragmentation
and could be treated by a dopamine agonist at bedtime
[10]. Nocturia and pain must be treated accordingly. As
a consequence of sleeping problems, daytime sleepiness
may appear, sometimes worsened by the use of dopa-
mine agonists.
Apathy
Apathy occurs in 16.5 [43] to 42% [44] of PD patients. It
is common and a main feature in end-stage PD and
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seems that apathy is associated with cognitive impair-
ment and depression and these should first be properly
treated [45]. Based upon current clinical evidence, it is
not clear whether apathy is improved by levodopa
treatment.
Autonomic dysfunction
80% of PD patients suffer from autonomic dysfunction
and it may be a cause of significant morbidity [46].
Autonomic symptom severity in patients with PD seems
to correlate with older age, greater disease severity, psy-
chiatric complications, sleep disorders, and higher doses
of dopaminergic medication. Conspicuous dysautono-
mias in patients suffering from severe PD include bowel
and bladder abnormalities, gastrointestinal disorders,
orthostatic hypotension and sexual dysfunction.
Orthostatic hypotension
Moderate orthostatic hypotension occurs in at least 20%
of patients, correlates with disease duration, and may be
a result of PD medications or intrinsic to the disease
[46]. Orthostathism may result in deteriorating cognitive
function, gait instability, fatigue and generalized weakness
[29]. Non-pharmacological treatment entails increased so-
dium intake, compression stockings, improved hydration,
and raising the head of the bed on blocks to improve the
endocrinological regulatory system [47]. Pharmacological
treatments contain the use of the NSAIDs, the sympatho-
mimetic etilefrine, the mineralocorticoid fludrocortisone
or the adrenergic agonist midodrine [9]. Treatment with
droxidopa, a precursor of norepinephrine, has been
demonstrated to be effective, well tolerated and safe when
used to treat orthostatic hypotension in PD. A dose of 200
mg - 2,000 mg of droxidopa has been shown to increase
standing blood pressure and standing ability in PD
patients with orthostatic hypotension [48].
Gastrointestinal disorders
Constipation occurs commonly in PD patients [49] and is
caused by intrinsic disease factors, medications, and
reduced fluid intake [50]. In late-stage disease, constipa-
tion can be severe, particularly in cases where the patient
is immobilized. It is one of the most common problems
and can cause extreme discomfort [51]. Constipation is
usually treated with stool softeners, lactulose, laxatives,
increased water intake, dietary bulk, or exercise [34]. In all
cases, anticholinergic agents should be discontinued [29].
Laxatives are important in preventing and managing con-
stipation, but bulking agents, faecal softeners, osmotic
agents and stimulant laxatives may be associated with
complications like abdominal pain or diarrhea, especially
after prolonged use [6]. Laxatives may not always be ne-
cessary if other remedies, e.g. dietary modification, can beused, assuming the patient is eating enough. It is better to
give laxatives once or twice-weekly, so avoid daily use of
stimulant laxatives [6].
Urologic dysfunction
Bladder dysfunction occurs in up to 70% of patients and
is characterized by detrusor muscle hyperactivity, which
leads to nocturia, urgency and increased urinary fre-
quency [34,46]. It is imperative to rule out other causes
of urologic dysfunction (urinary tract infection, prostate
hypertrophy for men and stress incontinence for
women) [29]. Patients should be particularly questioned
about urinary symptoms and, when having urinary pro-
blems, instructed how to use toileting schedules pads
and taught about fluid restriction at evenings, with botu-
linum injections into the prostate or bladder wall. If the
dysfunction is due to detrusor muscle hyperactivity, it
may be helpful to treat it with the antimuscarinic agents
tolterodine or oxybutynin, however with caution due to
the risk of impairing the mental state [10]. Tricyclic anti-
depressants with anticholinergic properties can also be
useful by reducing bladder irritability [29]. Botulinum
injections into the prostate or bladder wall could be
helpful in some patients [34]. A urinary sheath or cath-
eter is also an option if the dysfunction is highly signifi-
cant and troublesome.
Pain
Pain occurs in up to 50% of PD patients, occurs
throughout the disease, and remains an underre-
ported complication of end-stage PD [6]. It can stem
from a number of factors including musculoskeletal
causes, motor, and non-motor complications. The
most common motor causes are limb rigidity and
dystonia. The success of treatment depends on iden-
tifying the type of pain experienced. If the pain gets
worse in the “off” state, the treatment then should
aim to maintain the “on” state of medication. If the
pain is unrelated to levodopa doses, it should be
treated with general pain management protocols
[29]. Camptocormia is a stooped posture with flexion
of the thoracolumbar spine. It is exaggerated with
standing and causes back pain and spasm. Patients
may respond to botulinum toxin injections to the
rectus abdominus, physical therapy, and “sensory
tricks” [52]. For pain symptoms, opiates should be
used with caution, taking into consideration the
increased risk of constipation in the end-stage PD
patient with coexisting gastroparesis. Often all that
is required is careful adjustment of anti-PD medica-
tion. Simple analgesics for musculoskeletal pain and
adjuvants such as gabapentin for neuropathic pain
are options pending careful evaluation of pain his-
tory [10].
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Dysphagia is a common problem of late-stage PD, oc-
curring in up to 95% of individuals, and is associated
with aspiration pneumonia. Dysphagia is the result of
disruption in the process of coordinated contraction
and relaxation of the masticatory muscles, tongue, phar-
ynx, and esophagus. Dysphagia raises the probability of
recurrent aspiration owing to impaired coordination of
pharyngeal muscles. It may lead to aggravation of motor
symptoms due to reduced capability of taking anti PD
therapy orally [9]. Swallowing difficulty materializes
most obviously when choking on liquids. This problem
can often be alleviated by altered consistencies, safe
swallowing techniques and hand feeding, taking enough
time to do this properly to ease swallowing and reduce
the risk of aspiration [53]. If PD patients are experien-
cing significant swallowing dysfunction despite the alle-
viating measures, they should consult a speech
pathologist and undergo swallow exam study using
fluoroscopy. Recently, Christopher Kenney et. al have
shown that the rotigotine patch is effective, leading to
improved swallowing function in dysfunctioning
patients [54].
PEG feeding tubes can be considered if nutrition or
hydration is in danger of becoming inadequate or weight
loss exacerbates the general condition. However, PEG in-
sertion should only occur after careful consideration of
the risks and benefits with careful explanation of these
to the family. In end-stage PD, it is unlikely that PEG
placement will improve medical results, but it may delay
the decline to reach non-medical goals. Because dyspha-
gia is usually better in “on” time and worse in “off” time,
treatment should aim to increase “on” periods by adjust-
ing dopaminergic therapy [28]. In additon, training and
rehabilitation interventions now focus on repetitive
practice; this also applies to swallowing as much as to
walking or dressing.
Respiratory failure normally stems from hypoventilation
or vocal cord adduction, and could be helped by proper
anti-PD medication together with speech therapy. In
severe cases, Non Invasive Positive Pressure Ventilation
(NIPPV) or tracheostomy with assisted ventilation is an
option [9].
Pressure ulcers
As the disease reaches advanced or terminal stages, the
risk of soft tissue ulceration becomes significant [55].
The development of pressure ulcers can lead to a de-
crease of physical, emotional, social and mental quality
of life [56]. Because of the altered body position in PD,
the ulcers may occur in other places than bony promi-
nences. Caregivers need training in risk factors and tech-
niques for moving and handling the patients. Physical
activity can help to prevent contractures and painresulting from immobility [10]. Active or passive move-
ments in bed-bound patients can help to prevent con-
tractures, breathing exercises can help preventing
hypostatic pneumonia and frequent position changes
can help preventing pressure ulcers.Institutional care
While most PD patients will cope at home for many
years often with help of family caregivers as well as pro-
fessional caregivers, increasing disability, dependency,
psychotic, or harmful behavioral symptoms can precipi-
tate nursing home placement [57]. Psychiatric comor-
bidity may also often occur in caregivers themselves
because of the struggle they have caring for the patient
[58]. Caregiver burden in PD correlates with increas-
ing patient dependency and disability, depression, hal-
lucinations, and falls [59]. Institutional care might
therefore function as a relief of responsibilities for
caregivers.
The principal goals of institutional care are to prevent
complications, minimize distress, maintain patient dig-
nity and provide counseling and symptom relief [60]. In
institutional care, life-prolonging therapy is gradually
substituted by palliative measures as the disease pro-
gresses [5]. The patient and family are supported by the
multidisciplinary skills of the hospice team through end-
of-life care which includes bereavement services for fam-
ilies [61]. The issues of withholding and withdrawing life
prolonging treatment, and best interests decision making
as well as letting patients die should also be considered.
A multidisciplinary team approach can peacefully lead
a patient from disability to death [9]. Earlier studies have
shown that patients who received institutional care had
improved pain management, fewer emergency care hos-
pitalizations, fewer invasive procedures, and adequate
end-of-life care [62]. Meeting all the needs of PD
patients in a palliative state is a hallmark of institutional
care with an overriding objective to let the patients end
their life in a professional and comfortable environment.Conclusions
During the later stages, the palliative care model is intro-
duced to provide the patient with comfort and support.
The focus of treating motor complications in end-stage
PD needs to increase the time with no dyskinesias and
decreasing occurrence of motor and non-motor off
times. In advanced PD patients, the focus of treatment
shifts to treating the predominant non-motor symptoms
and having a more supportive and palliative nature.Competing interests
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